Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you are on Wegovy and wondering whether sweets are now completely off the table, the short answer is no — but the longer answer is more interesting. Semaglutide changes how your brain and gut respond to high-sugar foods, and many people find that cravings shift noticeably on treatment. These are prescription-only medicines assessed and prescribed individually, so your prescriber's guidance always takes precedence over general advice. What follows explains the biology, the practical picture, and what is worth discussing at your next clinical review.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture the scenario many people describe after their first few weeks on Wegovy: the usual Saturday chocolate ritual, and (halfway through) you stop. Not because you made a decision, but because you simply don't want any more. That experience is common enough that researchers have looked at why it happens.
Semaglutide activates GLP-1 receptors in the gut and brain. One of the effects is on the reward circuitry involved in food cravings, including cravings for sugar and fat-dense foods. The NHS medicines information on semaglutide explains that it works by reducing appetite and food intake; the appetite reduction is not limited to volume, it extends to the drive toward particular foods, especially highly palatable ones. Studies within the STEP programme observed that participants on semaglutide 2.4mg spontaneously reduced their intake of sweet and fatty foods more than would be explained by general appetite suppression alone.
This does not mean sweets cause a medical problem. It means the pull toward them often weakens. Some people find this reassuring. Others find it strange and, at first, slightly disorienting, worth acknowledging rather than glossing over.
The practical upshot: if you are building a sustainable eating plan on Wegovy, you may find sweet foods naturally fall out of the picture without the white-knuckle willpower that dieting usually demands. Whether that happens to the degree described above depends on the individual and the dose.
There is a misconception worth setting down gently: some people begin Wegovy expecting that they will be completely indifferent to sugar from week one. In practice, cravings shift gradually over the titration schedule, and early in treatment the more pressing issue is that sugar-heavy foods can worsen nausea.
Wegovy slows gastric emptying, food leaves your stomach more slowly than usual. When you eat a high-sugar food on an already-full or slow-clearing stomach, you may experience quicker onset of nausea, bloating, or reflux. This is particularly noticeable after a dose increase, when GI side effects can temporarily resurface. Cakes, sweets, sugary drinks and processed snack foods all fall into the category most likely to tip an unsettled stomach over into discomfort.
This is not an argument for permanent abstinence. It is an argument for timing. Many people find that small amounts of sweet food tolerated mid-meal land better than eating them in isolation on an empty stomach. Others find that the problem resolves once they have stabilised at a dose for a few weeks.
If you are finding nausea difficult to manage, the detail on managing what you eat while on Wegovy covers practical strategies around meal size and food types, and the question of what to do when eating feels difficult has its own answers at not eating on Wegovy.
The semaglutide NHS medicines page lists nausea, vomiting, diarrhoea and constipation as the most common side effects, typically most noticeable at the start of treatment or after a dose step up.
Rather than building your diet around a list of forbidden foods, most clinical guidance for people on GLP-1 medicines points toward what to include. Protein is the headline. Because Wegovy reduces overall food intake, getting enough protein to preserve muscle mass takes deliberate effort, not large portions, but protein-first at each meal. Eggs, fish, chicken, Greek yoghurt, legumes and cottage cheese all work well in small quantities.
Fibre from vegetables, pulses and wholegrains helps maintain gut motility, which matters when gastric emptying is already slowed. Hydration is frequently overlooked; the reduced drive to eat can carry over into a reduced drive to drink, and mild dehydration compounds fatigue and constipation.
Sweet foods, if you still want them, are better placed as a small addition to a balanced meal than as a standalone snack. For anyone building a more structured approach, the broader guidance on what to eat on Wegovy sets out food choices by category, and the fuller picture of eating on Wegovy covers the principles together. Your prescriber or a registered dietitian can adapt these principles to your own preferences and circumstances.
It is also worth knowing that the cost of treatment is sometimes a concern for people deciding whether to continue, the Wegovy price comparison page explains how UK pricing works across different providers, so you can make an informed decision.
Most changes in appetite and food preferences on Wegovy are expected and manageable. A few situations warrant a direct conversation with your clinical team rather than self-adjustment.
If nausea is severe enough that you cannot maintain adequate fluid intake, that is a clinical concern, dehydration on a GLP-1 medicine can affect kidney function. Similarly, if you find that reduced appetite has led to very low overall food intake for more than a few days, your prescriber should know.
There is also the question of relationship with food more broadly. Wegovy changes how food feels emotionally for some people, reduced pleasure in eating, a sense of detachment from meals that used to be enjoyable. This is worth naming to your clinical team, not internalising. It does not happen to everyone, but it is reported, and support is available. The team at nume's clinical team (sorry, at our pharmacy) reviews patients before every repeat, specifically so that these kinds of changes can be flagged and addressed.
If sweet foods have historically been connected to emotional patterns that feel harder to manage now that the usual coping mechanism has shifted, speaking to a GP or counsellor is a reasonable step alongside treatment. The general FAQs cover some of the most common questions our prescribers receive; for anything more specific, getting in touch directly is always an option.
Wegovy is a prescription medicine assessed individually. If you are considering treatment and want to understand whether it is suitable for your circumstances, starting a free consultation is the first step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.